Panelists discuss how upcoming oral selective estrogen receptor degraders (SERDs; eg, camasertinib, imlunestrant, and giredestrant) are showing efficacy primarily in populations with ESR1 mutations and are all well-tolerated oral agents that will likely receive approvals.
Panelists discuss how elacestrant from the EMERALD trial is being incorporated into practice based on ESR1 mutation status and duration of prior CDK4/6 inhibitor therapy, with combination approaches being explored in the ELEVATE trial.
Panelists discuss how the SERENA-6 trial design uses circulating tumor DNA (ctDNA) monitoring to detect ESR1 mutations and switch patients from aromatase inhibitors to oral selective estrogen receptor degraders (SERDs) such as camasertinib while continuing CDK4/6 inhibitors.
Panelists discuss how they will review the latest updates in hormone receptor–positive, HER2-negative, and HER2-low metastatic breast cancer, focusing on oral selective estrogen receptor degraders (SERDs), targeted therapies, and antibody-drug conjugates presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Panelists discuss the most exciting data and studies presented at the San Antonio Breast Cancer Symposium (SABCS) that show promise for improving outcomes in both HR-positive (HR+) and HER2-negative (HER2–) metastatic breast cancer and early-stage triple-negative breast cancer (TNBC), highlighting how precision medicine has enhanced outcomes and the overall patient experience.
Panelists discuss factors influencing the decision to continue adjuvant immunotherapy for patients achieving pathologic complete response (pCR) with pembrolizumab-containing therapy, weighing the benefits against risks and considering the role of biomarkers. They also explore sequencing decisions for patients with both BRCA mutations and early-stage triple-negative breast cancer (TNBC), focusing on the prioritization of PARP inhibition versus immunotherapy and situations where both may be recommended. Additionally, they discuss approaches to monitoring and managing immune-related adverse events, including baseline screening and ongoing management protocols.
Panelists highlight the KN-522 study and discuss how updated KEYNOTE-522 data influence their selection of patients for pembrolizumab-containing regimens, focusing on factors that guide the decision to recommend immunotherapy and how to approach patients with borderline indications.
Panelists discuss how recent data inform their approach to PARP inhibitor use in the metastatic setting, exploring the role of PARP inhibition for somatic BRCA mutations and strategies for managing PALB2 and other homologous recombination deficiency mutations.
Panelists review the recent OlympiA data presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) and discuss how the findings influence their approach to sequencing adjuvant olaparib with other systemic therapies for breast cancer patients.
Panelists discuss their approach to BRCA testing in early-stage versus metastatic breast cancer patients, highlighting the 2024 American Society of Clinical Oncology (ASCO) guidelines for germline testing and exploring which patients are not tested for BRCA, as well as how they differentiate between germline and somatic testing approaches.
Panelists discuss the factors influencing the choice between abemaciclib and ribociclib for adjuvant CDK4/6 inhibitor therapy, including patient characteristics and safety profiles, and explore strategies for toxicity management, maintaining dose intensity, and addressing adherence or toxicity challenges in real-world clinical practice.
Panelists discuss the recent data from the NATALEE and monarchE studies, focusing on adjuvant CDK4/6 inhibitor selection for high-risk HR-positive/HER2-negative (HR+/HER2–) early breast cancer patients, and explore how to interpret the different efficacy signals, particularly the early curve separation observed in monarchE versus NATALEE.
